News Alvotech

Equities

ALVO

LU2458332611

End-of-day quote Nasdaq Other stock markets 03:30:00 15/05/2024 am IST			5-day change	1st Jan Change
13.35 ^USD	0.00%		-1.84%	+16.29%

30/04	Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	MT
30/04	Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alvotech S.A. Annual General Meeting to be held June 7, 2024	15/05	GL
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)	13/05	AQ
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)	13/05	GL
Alvotech : General Meeting Alvotech - Convening Notice (AGM 2024)	06/05	PU
Alvotech Announces Positive Topline Results From Confirmatory Clinical Study For Its Proposed Golimumab Biosimilar	02/05	AQ
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024	02/05	GL
Alvotech - U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-FreeInterchangeable Biosimilar to Humira	01/05	AQ
Alvotech And Teva's Selarsdi™ (ustekinumab-aekn), Biosimilar To Stelara® Approved By FDA	01/05	AQ
Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	30/04	MT
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	30/04	MT
Alvotech Announces U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira	30/04	CI
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)	30/04	GL
FDA Approval Of Alvotech/Teva Ustekinumab Biosimilar	26/04	AQ
Cigna to offer Humira rivals with $0 copay at specialty pharmacy	26/04	RE
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi	25/04	AQ
Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study	24/04	MT
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)	24/04	GL
Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi	24/04	CI
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira	22/04	AQ
Sector Update: Health Care Stocks Advance Late Afternoon	20/04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Alvotech

Equities

ALVO

LU2458332611

Summary

Filters